CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$6.23
-0.02 (-0.32%)
▼
5d:
-1.74%
30d:
+4.71%
90d:
+4.53%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 22, 2026
27d
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CSBR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $6.23, which is considered slightly high relative to its 30-day fair value range of $5.71 to $6.39. The stock's valuation (Forward PE: 62.3) is in line with its historical norms (57.1). At these levels, the market is pricing in 3.0% annual earnings growth.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.60, while resistance sits at $7.00.
Market Sentiment: CSBR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.00 (+92.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSBR is in a downtrend. Immediate support is located at $5.60, while resistance sits at $7.00.
Market Sentiment: CSBR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.00 (+92.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.71 -
$6.39
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 92.6% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 3.0% growth with -2.8% revenue growth
Trading Range Analysis
30-Day Trading Range
$5.71 -
$6.39
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.60
Resistance Level
$7.00
Current Trend
Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
62.30
Wall Street Target
$12.00
(+92.6%)
Revenue Growth (YoY)
-2.8%
Earnings Growth (YoY)
-61.1%
Profit Margin
-4.0%
Valuation Premium vs History
+3.0% premium
PE vs Historical
62.3 vs 57.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.0%
(market-implied from PE analysis)
1-Year Target
$6.42
(+3%)
2-Year Target
$6.61
(+6%)
3-Year Target
$6.81
(+9%)
3-Yr Target (if PE normalizes)
(PE: 62→57)
PE COMPRESSION
$6.24
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 62.3, Growth: -16.7%)
$4.54
(+-27%)
Base:
(SPY PE: 21.8, Growth: -16.7%)
$1.59
(-75%)
Bear:
(PE: 18.5, Growth: -16.7%)
$1.35
(-78%)
Share & Embed Analysis
Last updated: June 24, 2026 3:07 AM ET
Data refreshes hourly during market hours. Next update: 4:07 AM
Data refreshes hourly during market hours. Next update: 4:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
